Every 8-K that Instil Bio, Inc. (TIL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TIL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TIL filings page.
Instil Bio, Inc. reported second quarter 2026 results, highlighting a strong cash position and much lower operating costs while it evaluates potential acquisitions and in-licensing opportunities for novel therapeutics. As of June 30, 2026, cash, cash equivalents, restricted cash and marketable securities totaled $69.9 million, down from $76.3 million at December 31, 2025, and are expected to fund the current operating plan beyond 2027.
Operating expenses for the quarter fell to $5.6 million from $23.4 million a year earlier, driven by in-process R&D dropping to nil, research and development declining to $0.3 million, and restructuring and impairment charges falling sharply. General and administrative expense also decreased to $5.1 million. Net loss for the quarter narrowed to $4.3 million, or $0.63 per share, compared with $21.4 million, or $3.24 per share, in the prior-year quarter. On a non-GAAP basis, which excludes non-cash stock-based compensation and restructuring and impairment charges, quarterly net loss improved to $3.1 million, or $0.45 per share, versus $19.0 million, or $2.88 per share, a year earlier.
Instil Bio, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Of 6,781,976 common shares outstanding as of the record date, 5,757,919 shares, or approximately 84.9%, were present or represented by proxy, indicating strong shareholder participation.
Stockholders elected Class II directors George Matcham and Neil Gibson to serve until the 2029 Annual Meeting. Matcham received 3,683,114 votes for and 742,925 withheld, while Gibson received 3,603,901 votes for and 822,138 withheld; each had 1,331,880 broker non-votes. Stockholders also ratified the selection of RSM US LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 5,750,869 votes for, 6,911 against and 139 abstentions.
Instil Bio reported first quarter 2026 results showing a much smaller loss and a solid cash position while it evaluates potential acquisitions and in-licensing opportunities for new therapeutics. As of March 31, 2026, the company held about $74.7 million in cash, cash equivalents, restricted cash and marketable securities and expects this to fund its current operating plan beyond 2027.
Net loss for the quarter was $4.2 million, or $0.62 per share, compared with $28.2 million, or $4.32 per share, a year earlier. On a non-GAAP basis, excluding stock-based compensation and restructuring and impairment charges, net loss was $2.2 million, or $0.32 per share, versus $8.6 million, or $1.32 per share.
Operating expenses declined sharply, with research and development at $0.7 million, general and administrative at $5.3 million, and restructuring and impairment charges at $1.0 million, all down significantly from the prior year period. Management highlighted an ongoing strategic shift toward building a focused pipeline through externally sourced assets, while cautioning there is no assurance any transaction will occur.
Instil Bio, Inc. is changing its independent auditor. The Audit Committee appointed RSM US LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, replacing Deloitte & Touche LLP, which was dismissed effective April 1, 2026.
Deloitte’s reports on the 2024 and 2025 consolidated financial statements contained no adverse opinions, disclaimers, or qualifications. The company reports no disagreements with Deloitte on accounting, disclosure, or audit scope, and no reportable events. Instil Bio also states it has not previously consulted RSM on accounting matters described in Regulation S‑K Item 304(a)(2).
Instil Bio reported its fourth quarter and full year 2025 results while outlining a strategic shift toward acquiring or in‑licensing new therapeutic candidates. In January 2026, its subsidiary Axion Bio discontinued clinical development of AXN-2510 and terminated a related license and collaboration agreement.
Cash, cash equivalents, restricted cash and marketable securities totaled $76.3 million as of December 31, 2025, down from $115.1 million a year earlier, and are expected to fund the current operating plan beyond 2027. For 2025, research and development expenses were $24.7 million, general and administrative expenses were $27.2 million, and restructuring and impairment charges were $16.6 million.
Instil reported a 2025 net loss of $71.4 million, or $10.70 per share, compared with a net loss of $74.1 million, or $11.39 per share, in 2024. On a non‑GAAP basis, excluding stock‑based compensation and restructuring and impairment charges, 2025 net loss was $46.1 million or $6.91 per share, an improvement from $49.4 million or $7.59 per share in 2024.
Instil Bio, Inc. (TIL) furnished a corporate update and financial results for the quarter ended September 30, 2025, via an accompanying press release.
The update was provided under Item 2.02 and the information is being furnished, not filed. Detailed results are included in Exhibit 99.1 to the report.
Instil Bio, Inc. furnished an 8-K reporting a corporate update and its financial results for the quarter ended June 30, 2025. The company said the details appear in a press release filed as Exhibit 99.1 to the 8-K and that the information is being furnished (not "filed") under the Securities Exchange Act. No financial figures, operational details, or other substantive results are included in the 8-K text itself; readers are directed to the attached press release for the actual results.